The new semaglutide binge eating study found improvements in eating control and body-image worries during obesity treatment. It didn't establish that binge episodes fell more than with placebo, an inactive comparison treatment. Both findings matter.

Binge eating means eating an unusually large amount in a short time while feeling unable to control the eating. Loss-of-control eating means feeling unable to control eating even when the amount isn't unusually large.

The results offer some reassurance for people considering obesity care. They don't establish semaglutide as a treatment for binge-eating disorder, an illness involving recurring binges and marked distress.

What the semaglutide binge eating study found

As of November 19, 2026, the day this article was written, a Penn trial published online November 15 in the International Journal of Eating Disorders adds new evidence about eating behaviors during obesity treatment.

Researchers assigned 120 adults by chance, in a three-to-two ratio, to semaglutide 2.4 mg or placebo. Both groups received lifestyle support for 60 weeks. A prescriber sets an individual patient's dose. Clinician interviews and questionnaires assessed eating behaviors, body image and mood.

The trial registration allowed adults aged 18–70 with obesity, or overweight plus a related health condition. It excluded diabetes and bulimia diagnosed within the previous five years. Bulimia involves binges followed by behaviors intended to offset eating. This was an obesity-treatment population, with eating-disorder symptoms measured along the way.

Semaglutide copies GLP-1, a gut-hormone signal involved in appetite and blood sugar. In Penn's November 17 announcement, average weight loss was approximately 15% with semaglutide versus about 3% with placebo after 60 weeks.

Penn reported greater improvements in eating control, distress about weight and shape, and body dissatisfaction. Its release also disclosed partial funding from the drug's manufacturer, Novo Nordisk, which it said had no role in conducting or reporting the study.

What this means for someone prescribed semaglutide

A change in appetite is only one part of someone's relationship with food. The findings give clinicians a reason to ask about distress, eating control and body image during follow-up, alongside weight.

Eating-disorder care can include therapy, medical monitoring and nutritional counseling. Someone can need that care at any body weight. Food noise, the phrase for intrusive food thoughts, describes another experience and isn't itself a diagnosis.

What it does not show about binge-eating disorder

The reduction in binge episodes was not significantly different between semaglutide and placebo. That means this comparison did not establish a clear advantage for reducing the number of episodes.

The paper's abstract reports that 31 participants had binge episodes at the start. Eighteen had binge-eating disorder or a similar pattern that fell short of the full diagnosis. These small groups were more likely to report no binge episodes with semaglutide than placebo.

That finding deserves follow-up. It cannot establish how well the medicine works in a larger population seeking treatment specifically for binge-eating disorder.

The authors also describe important limits. More placebo participants left the study, leaving missing follow-up information. The analyses explored many outcomes without adjusting for the extra chance of a false alarm. Results need confirmation in trials designed around eating-disorder outcomes.

Does the result apply to tirzepatide?

The Penn trial did not test tirzepatide or compare the two medicines. Its results cannot rank them for eating-disorder symptoms.

Tirzepatide also comes up in weight-management visits, so the same history of restriction, binge eating or purging belongs in that conversation. Purging means behaviors such as intentional vomiting or laxative misuse after eating. A different medicine still needs its own evidence and an individual assessment.

An eating-disorder history belongs in the visit

Anyone with current or past eating-disorder symptoms needs that history considered before starting an appetite-suppressing medicine. The trial authors' safety statement is clear:

Disordered eating behaviors were rare but did occur, suggesting the need for periodic monitoring in at-risk individuals.

As of November 19, 2026, the day this article was written, expert recommendations published online September 15 in World Psychiatry call for screening before treatment and monitoring during it. This is expert consensus, meaning structured agreement among specialists and people with lived experience, rather than a drug trial.

The panel says these medicines should generally be avoided in active eating disorders, particularly anorexia, including its atypical form. Anorexia involves severe food restriction and fear of weight gain; its atypical form can occur without low body weight. The same advice to avoid covers bulimia with marked restriction or weight substantially below the person's previous level, and the panel says clinicians should proceed cautiously when there is a past history of these disorders.

These conditions raise concerns beyond binge frequency. The National Eating Disorders Association lists risks including misuse of these drugs in restrictive eating disorders, rapid weight loss and malnourishment, and an inability to eat meals and snacks at regular intervals. It calls for discussion with an eating-disorder specialist and the prescribing provider before treatment.

If disordered eating emerges, the authors call for referral to an appropriate mental health professional. Semaglutide and depression covers the separate mood question. ANAD's eating-disorder helpline offers emotional support and referrals.

Where the FDA status and compounded medication fit

As of November 19, 2026, the day this article was written, semaglutide has approved uses, but it is not FDA-approved for binge-eating disorder. The Wegovy label marked “Revised: 06/2026” does not list that use.

An FDA review identifies lisdexamfetamine as the only drug approved for binge-eating disorder. Its Vyvanse label, revised 04/2026, covers moderate to severe disorder in adults and says it is not indicated for weight loss. That label carries a boxed warning for abuse, misuse and addiction, which can lead to overdose and death. Therapy remains part of eating-disorder care.

Compounded means prepared by a pharmacy for a prescription. Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

What to watch next

Larger trials focused on diagnosed binge-eating disorder would help clarify the early findings. Longer follow-up also matters for uncommon harms and whether improvements last. The Penn results cannot establish the same outcomes for a compounded preparation.

The study of GLP-1 use without documented obesity or diabetes raises a related question: what health problem is treatment intended to address? A clear goal and a plan to monitor eating behaviors belong together.

At Promise, a licensed provider reviews every request and prescribes or declines based on medical eligibility; not everyone qualifies.